ESSA Pharma (NASDAQ:EPIX) Issues Quarterly Earnings Results

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) issued its earnings results on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), Zacks reports.

ESSA Pharma Trading Down 1.8 %

EPIX opened at $1.66 on Tuesday. The business’s 50 day moving average is $1.72 and its 200-day moving average is $3.70. The stock has a market cap of $73.69 million, a PE ratio of -2.59 and a beta of 1.60. ESSA Pharma has a twelve month low of $1.40 and a twelve month high of $10.94.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Oppenheimer lowered ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Finally, Piper Sandler downgraded shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $15.00 to $2.00 in a report on Monday, November 4th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.